Study of DSP-7888 in Patients With Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

DSP-7888

3.5-10.5 mg/body,Id every 2-4 weeks

Trial Locations (16)

Unknown

Japanese Red Cross Narita Hospital, Narita

Chugoku Central Hospital, Fukuyama

Yokohama Municipal Citizen's Hospital, Yokohama

Kochi Medical School Hospital, Nankoku

Sendai Medical Center, Sendai

Kurashiki Central Hospital, Kurashiki

Kindai University Hospital, Sayama

Osaka University Hospital, Suita

Tokyo Metropolitan Geriatric Hospital, Itabashi-ku

Japanese Red Cross Medical Center, Shibuya-ku

NTT Medical Center Tokyo, Shinagawa-ku

Keio University Hospital, Shinjuku-ku

National Hospital Organization Disaster Medical Center, Tachikawa

Kyushu University Hospital, Fukuoka

National Hospital Organization Kyushu Medical Center, Fukuoka

Okayama City General Medical Center Okayama City Hospital, Okayama

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02436252 - Study of DSP-7888 in Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter